Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind Phase IIb Study to Evaluate the Safety and Efficacy of Different Doses of Tyrosine Adsorbed Ragweed Allergoid With MPL® With a Single-Blind Portion to Evaluate the Residual Allergenicity in Skin Test in Patients Sensitized to Ragweed Pollen.

NCT00258635 is registered in ClinicalTrials.gov with Allergy Therapeutics as lead sponsor.

NCT NCT00258635
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00258635 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind Phase IIb Study to Evaluate the Safety and Efficacy of Different Doses of Tyrosine Adsorbed Ragweed Allergoid With MPL® With a Single-Blind Portion to Evaluate the Residual Allergenicity in Skin Test in Patients Sensitized to Ragweed Pollen.
Lead sponsor
Allergy Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2005
Completion date
August 7, 2006
Enrollment
69 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

type i hypersensitivity